iShares Biotechnology ETF (IBB)
| Assets | $5.37B |
| Expense Ratio | 0.45% |
| PE Ratio | 18.58 |
| Shares Out | 41.70M |
| Dividend (ttm) | $0.38 |
| Dividend Yield | 0.29% |
| Ex-Dividend Date | Mar 18, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 5.34% |
| Volume | 204,087 |
| Open | 132.77 |
| Previous Close | 133.65 |
| Day's Range | 131.47 - 133.03 |
| 52-Week Low | 107.43 |
| 52-Week High | 150.57 |
| Beta | 0.73 |
| Holdings | 261 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
47.21% of assets| Name | Symbol | Weight |
|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 7.99% |
| Amgen Inc. | AMGN | 7.58% |
| Gilead Sciences, Inc. | GILD | 7.58% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.48% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 4.51% |
| IQVIA Holdings Inc. | IQV | 3.13% |
| Mettler-Toledo International Inc. | MTD | 2.84% |
| argenx SE | ARGX | 2.41% |
| Natera, Inc. | NTRA | 2.36% |
| Waters Corporation | WAT | 2.34% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 18, 2025 | $0.12117 | Mar 21, 2025 |
| Dec 17, 2024 | $0.06237 | Dec 20, 2024 |
| Sep 25, 2024 | $0.20047 | Sep 30, 2024 |
| Mar 21, 2024 | $0.12599 | Mar 27, 2024 |
| Dec 20, 2023 | $0.12396 | Dec 27, 2023 |
| Sep 26, 2023 | $0.15316 | Oct 2, 2023 |
Performance
IBB had a total return of -3.49% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.01%.
News
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...
5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs
The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fuelin...
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
IBB: Now Is The Time To Be Contrarian
Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Political pressure and persistently high interest rates have some wondering if the industry's model is broken.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides mor...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
How tariffs could impact pharma and early-stage healthcare investments
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
iShares Biotechnology ETF: Playing Defense
The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is retu...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.